Clinical trials: Neuron Disease, Motor
Spinal Muscular Atrophy, Neuromuscular Disease
Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)
This study is being conducted to test whether exercise can be effectively used as an intervention to treat Spinal Muscular Atrophy (SMA).
- Trial name
- NCT01166022
- Testing
- Exercise
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Columbia University
Amyotrophic Lateral Sclerosis
Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients
This study evaluated the influence of a tailored aerobic exercise protocol on the functional outcome in ALS patients. In addition, the investigators compare some CPET variables collected during exercise testing in both groups.
- Trial name
- NCT03326622
- Testing
- standard care, moderate exercise
- Volunteers
- 48 people
- Sponsor
- University of Lisbon
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
EEG and TMS-based Biomarkers of ALS, MS and FTD
The purpose of this observational study is to improve understanding of the biology of why ALS, MS and FTD have different effects on different people and facilitate better measurement of the disease in future drug testing.
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Multiple Sclerosis
- Trial name
- NCT04918251
- Testing
- 128 electrode electroencephalography (EEG), Transcranial magnetic stimulation (TMS)
- Where
- Ireland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
Amyotrophic Lateral Sclerosis
A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
- Trial name
- NCT05039099
- Testing
- AP-101
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 73 people
- Sponsor
- AL-S Pharma
Amyotrophic Lateral Sclerosis
Polish Version Dyspnea in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis is a fatal disease with progressive degeneration of central and peripheral motor neurons. Weakness of pharyngeal and respiratory muscles lead to dyspnea, which is present in up to 80% of patients.
- Trial name
- NCT07178574
- Volunteers
- 120 people
- Sponsor
- Jakub Antczak
Chronic Stroke, Amyotrophic Lateral Sclerosis
Influence of G-CSF and EPO on Associative Learning and Motor Skills
In the study we want to prove whether the subcutaneous application of granulocyte-stimulating factor (G-CSF) and erythropoetin (EPO) influence associative learning and/or motor skills of patients, who suffer from chronic stroke…
- Trial name
- NCT00298597
- Testing
- granulocyte - colony stimulating factor (G-CSF), erythropoetin (EPO)
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- University Hospital Muenster
Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1)
Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
The primary aim is to characterize the prevalence, severity and quality of musculoskeletal nociceptive pain in adult patients with neuromuscular disorders (NMD).
- Conditions
- Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2, Spinal Muscular Atrophy Type 3
- Trial name
- NCT04907162
- Testing
- Beck depression inventory fast screen, German Pain Inventory, Brief Pain Inventory
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- LMU Klinikum
Amyotrophic Lateral Sclerosis
Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)
The study will evaluate the safety, tolerability and therapeutic effects of transplantation of escalating doses of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), in patients…
- Trial name
- NCT01777646
- Testing
- MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
- Where
- Israel
- Volunteers
- 14 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis
Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)
This was a 2-part study of dexpramipexole in patients with ALS. Part 1 was a randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, and clinical effects of oral administration of 3 dosage levels…
- Trial name
- CL201 (NCT00647296)
- Testing
- Dexpramipexole 50 mg/day, Dexpramipexole 150 mg/day, Dexpramipexole 300 mg/day
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis
Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons, leading to progressive muscle weakness and functional decline.
- Trial name
- NCT07467746
- Testing
- C. cicadae, Control
- Volunteers
- 84 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Spinal Muscular Atrophy
Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen
Risdiplam Exchange (RISE) is a study of spinal muscular atrophy (SMA) patients who crossover to 36 months of open-label risdiplam monotherapy following a comparable period of nusinersen treatment.
- Trial name
- RISE (NCT05522361)
- Testing
- Risdiplam
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Clinic for Special Children
Muscular Atrophy, Spinal
A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients
The objectives of this trial are: to establish a safety profile for use of Hydroxyurea in children with Type I Spinal Muscular Atrophy; to identify reliable outcome measures for HU treatment in Type I SMA; and to detect the…
- Trial name
- NCT00568698
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Stanford University
Amyotrophic Lateral Sclerosis
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS.
- Trial name
- NCT04516096
- Testing
- AMX0035
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Muscle Spasticity, Healthy
Physiologic Studies of Spasticity
This study will provide information about changes that occur in the motor neurons of the spinal cord (the nerve cells that control the muscles) when the motor cortex (the region of the brain that controls movement) is unable to…
- Trial name
- NCT00014976
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Foot Drop, Thigh Muscles Weakness (Hamstrings or Quadriceps)
Evaluation of the Safety and Performance of the NESS L300 Plus System
The study is designed to evaluate the safety and efficacy of using the L300 Plus as a neuroprosthesis device for walking in patients following an UMN injury or disease.
- Conditions
- Foot Drop, Thigh Muscles Weakness (Hamstrings or Quadriceps), Upper Motor Neuron Injury or Disease
- Trial name
- L300Plus (NCT01237860)
- Testing
- NESS L300 Plus System
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Bioness Inc
Spinal Muscular Atrophy
An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)
The primary objective of this study is to examine the safety and tolerability of nusinersen (ISIS 396443) administered intrathecally to participants with Spinal Muscular Atrophy (SMA) who previously participated in ISIS…
- Trial name
- NCT01780246
- Testing
- nusinersen
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Sleep Disorders and the Onset and Progression of ALS
200 cases of ALS patients were collected to explore whether sleep disorders are related to earlier onset age, and whether sleep disorders accelerate the progress of ALS and shorten the survival time of ALS patients.
- Trial name
- NCT04952038
- Testing
- sleep disorder
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Third Hospital
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects…
- Trial name
- NCT02478450
- Testing
- Q-Cells
- Volunteers
- 30 people
- Sponsor
- Q Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.
- Trial name
- NCT05299658
- Testing
- CNMAu8
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Clene Nanomedicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.